• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Implantable loop recorder associated with increased detection of atrial fibrillation post-ischemic stroke compared with external loop recorder

byJake EngelandMichael Pratte
June 2, 2021
in Cardiology, Chronic Disease, Neurology
Reading Time: 3 mins read
Propofol appears safe and effective in procedural sedation for cardioversion
Share on FacebookShare on Twitter

1. In patients with recent ischemic stroke and no diagnosed atrial fibrillation (AF), there were increased AF diagnoses in those who received an implantable loop recorder compared with those who received an external loop recorder within 12 months of the intervention.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Atrial fibrillation (AF) is one of the leading causes of ischemic stroke related to cardiac embolisms. Patients suffering from ischemic stroke without a history of AF should be observed with electrocardiographic monitoring for at least several weeks to determine if they have AF and begin anticoagulation medication. The PER DIEM randomized controlled trial compared AF incidences in patients with ischemic stroke without diagnosed AF using an external loop recorder for 30 days or an implantable loop recorder for 12 months. Three-hundred patients were randomized 1:1 to implantable or external loop recorder, and 259 (126 implantable and 133 external) were available for the 12-month follow-up visit. The development of AF (or highly probable AF) within 12 months was significantly higher in patients who received an implantable loop recorder compared with those with an external loop recorder. Within the first 30 days, there was no significant difference in AF diagnoses between groups; however, between 30 days and 12 months, there were significantly more AF cases in the implantable loop recorder cohort. Post hoc analysis revealed that age and device group were factors associated with the development of new AF diagnoses. The results from this trial indicate that in patients with ischemic stroke and no history of AF, implantable monitoring led to significantly greater detection of AF than external monitoring. One limitation of this study, however, is that monitoring only detected AF if the episode lasted 2 minutes or longer; this may have resulted in some missed diagnoses of AF if the episode was shorter than 2 minutes.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

2 Minute Medicine Rewind September 7, 2026

2 Minute Medicine Rewind August 31, 2026

In-Depth [randomized controlled trial]: This trial enrolled 300 adults (median [interquartile range] age: 64.1 [56.1-73.7] years) who had an ischemic stroke without a history of AF from 3 hospitals in Alberta between May 2015 and November 2017. Half were randomized to receive an implantable loop recorder for 12 months, and half were randomized to receive an external loop recorder for 30 days. The primary outcome was the development of AF (or highly probable AF) lasting for 2 minutes or greater within 12 months of the intervention. AF development within 12 months occurred in 23 out of 150 (15.3%) patients with an implantable loop recorder and 7 out of 150 (4.7%) with an external loop recorder at 12 months (RR: 3.29 [95% CI: 1.45-7.42]; p= 0.003). Within the first 30 days, there was no significant difference in AF diagnoses between groups. However, between 30 days and 12 months, there were 16 (10.7%) diagnoses of AF in the implantable loop cohort and 2 (1.3%) diagnoses of AF in the external loop cohort (RR: 8.00 [95% CI: 1.87-34.19]; p= 0.001). Most secondary outcomes displayed no significant differences between intervention groups. The combined outcome of AF development or death by 12 months was observed in 26 (17.3%) participants in the implantable loop cohort compared with 10 (6.7%) participants in the external loop cohort (HR: 2.64 [95% CI:1.27-5.49]; p= 0.009).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: arrhythmiasatrial fibrillationischemic stroke
Previous Post

Greater nurse staffing may improve patient outcomes and reduce costs

Next Post

#VisualAbstract: Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Weekly Rewinds

2 Minute Medicine Rewind August 31, 2026

August 31, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Catheter ablation within 1 year of atrial fibrillation diagnosis is associated with reduced risk of recurrence

July 24, 2026
Next Post
#VisualAbstract: Tezepelumab reduced annual exacerbation rates in patients with severe asthma

#VisualAbstract: Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Long‐term cardiovascular outcomes after pregnancy in women with heart disease

#VisualAbstract: Prolgolimab is efficacious and tolerable in patients with advanced melanoma

#VisualAbstract: Risk factors associated with speech and voice impairment in long-term survivors of oropharyngeal cancer

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The rate of urethrocutaneous fistula following caudal and penile blocks for hypospadias repair may be similar
  • Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma
  • Deep learning model improved cancer recurrence prediction for pediatric glioma using serial imaging
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.